This review also indicates that genetic studies on drug response to DPP-4i, GLP-1 RA and SGLT2i in type 2 diabetes have been mainly based on candidate genes, derived from aetiological processes or drug pathways. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.